Search

FAV-201

FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.

SNS-314

SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. … SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.

Zosuquidar

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States.

Pixantrone

Pixantrone does not bind iron and promotes the formation of reactive oxygen species to a lesser degree than other anthracyclines. … It also inhibits doxorubicinol formation in human myocardium. [3] As a result, it is believed to be less cardiotoxic while still exerting efficacy.

Alicaforsen

Amelubant

Arzoxifene

Incadronic acid

Incadronate, or YM-175,[A202769] is a nitrogen containing bisphosphonate.

Bimoclomol

Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.

Droxidopa

Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic orthostatic hypotension (NOH) as early as 2011. … Though L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout